This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04320342
Recruitment Status : Recruiting
First Posted : March 25, 2020
Last Update Posted : February 9, 2023
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Tracking Information
First Submitted Date  ICMJE March 23, 2020
First Posted Date  ICMJE March 25, 2020
Last Update Posted Date February 9, 2023
Actual Study Start Date  ICMJE April 28, 2022
Estimated Primary Completion Date July 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 23, 2020)
Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28 [ Time Frame: Week 28 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 6, 2023)
  • Change from baseline in 2-hour post-dose morning FEV1 at Week 28 [ Time Frame: Week 28 ]
  • Rate of moderate and severe COPD exacerbations over 52 weeks of treatment [ Time Frame: 52-week treatment period ]
    Annualized rate of moderate and severe COPD exacerbations as observed during the 52-week study treatment period.
  • Change from baseline in pre-dose morning FEV1 at designated clinic visits [ Time Frame: Week 4, Week 10, Week 40, & Week 52 ]
  • Change from baseline in 2-hour post-dose morning FEV1 designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 40, & Week 52 ]
  • Change from pre-dose to 2-hour post-dose morning FEV1 at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • FEV1 response (change from baseline in pre-dose morning FEV1 ≥100ml) at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Time to first moderate or severe COPD exacerbation [ Time Frame: 52-week treatment period ]
  • Rate of severe COPD exacerbations over 52 weeks of treatment [ Time Frame: 52-week treatment period ]
    Annualized rate of severe COPD exacerbations as observed during 52-week treatment period
  • Time to first severe COPD exacerbation [ Time Frame: 52-week treatment period ]
  • Saint George's Respiratory Questionnaire (SGRQ) response (a decrease from baseline in total score ≥4) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline in the SGRQ total score and domain scores at each designated clinic visit [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline to each inter-visit period in the percentage of days without intake of rescue medication [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) to each inter-visit period (defined as the period of time between designated clinic visits) in percentage of days without rescue medication
  • Change from baseline to each inter-visit period in the average use of rescue medication (number of puffs/day) [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average number of puffs per day of rescue medication for each inter-visit period (defined as the period of time between designated clinic visits).
  • Change from baseline in pre-dose morning Forced Vital Capacity (FVC) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline in 2-hour post-dose morning FVC at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
    Change from baseline (defined as the pre-dose value on Day 1) in 2-hour post-dose morning FVC at designated clinic visits
  • Change from pre-dose to 2-hour post-dose morning FVC at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline to each inter-visit period in the average E-RS total score and domain scores [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average E-RS total score and E-RS domain scores for the period of time between designated clinic visits.
  • Change from baseline in COPD Assessment Test (CAT) score at designated clinic visit [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
    The CAT is composed of 8 questions to measure the impact of COPD on daily life, which are scored from 0 to 5 with higher scores reflecting greater impact.
  • CAT response (decrease from baseline ≥2 points) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Modified Medical Research Council (mMRC) dyspnea scale at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
    Descriptive statistics of the mMRC dyspnea scale score at designated clinic visits. The mMRC dyspnea scale is graded from 0 to 4, with higher grades reflecting greater severity.
  • Change from baseline in health-related quality of life (decrease from baseline in total SGRQ score ≥4) over 52 weeks of treatment. [ Time Frame: 52-week treatment period ]
Original Secondary Outcome Measures  ICMJE
 (submitted: March 23, 2020)
  • Change from baseline in 2-hour post-dose morning FEV1 at Week 28 [ Time Frame: Week 28 ]
  • Rate of moderate and severe COPD exacerbations over 52 weeks of treatment [ Time Frame: 52-week treatment period ]
    Annualized rate of moderate and severe COPD exacerbations as observed during the 52-week study treatment period.
  • Change from baseline in pre-dose morning FEV1 at designated clinic visits [ Time Frame: Week 4, Week 10, Week 40, & Week 52 ]
  • Change from baseline in 2-hour post-dose morning FEV1 designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 40, & Week 52 ]
  • Change from pre-dose to 2-hour post-dose morning FEV1 at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • FEV1 response (change from baseline in pre-dose morning FEV1 ≥100ml) at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Time to first moderate or severe COPD exacerbation [ Time Frame: 52-week treatment period ]
  • Rate of severe COPD exacerbations over 52 weeks of treatment [ Time Frame: 52-week treatment period ]
    Annualized rate of severe COPD exacerbations as observed during 52-week treatment period
  • Time to first severe COPD exacerbation [ Time Frame: 52-week treatment period ]
  • Saint George's Respiratory Questionnaire (SGRQ) response (a decrease from baseline in total score ≥4) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline in the SGRQ total score and domain scores at each designated clinic visit [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline to each inter-visit period in the percentage of days without intake of rescue medication [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) to each inter-visit period (defined as the period of time between designated clinic visits) in percentage of days without rescue medication
  • Change from baseline to each inter-visit period in the average use of rescue medication (number of puffs/day) [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average number of puffs per day of rescue medication for each inter-visit period (defined as the period of time between designated clinic visits).
  • Change from baseline in pre-dose morning Forced Vital Capacity (FVC) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline in 2-hour post-dose morning FVC at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
    Change from baseline (defined as the pre-dose value on Day 1) in 2-hour post-dose morning FVC at designated clinic visits
  • Change from pre-dose to 2-hour post-dose morning FVC at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • Change from baseline to each inter-visit period in the average E-RS total score and domain scores [ Time Frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52 ]
    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average E-RS total score and E-RS domain scores for the period of time between designated clinic visits.
  • Change from baseline in COPD Assessment Test (CAT) score at designated clinic visit [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • CAT response (decrease from baseline ≥2 points) at designated clinic visits [ Time Frame: Week 4, Week 10, Week 28, Week 40, & Week 52 ]
  • mMRC dyspnea scale at designated clinic visits [ Time Frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52 ]
    Descriptive statistics of the mMRC dyspnea scale score at designated clinic visits
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Official Title  ICMJE A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Detailed Description

This is a phase III, multinational, multicenter, randomized, double-blind active controlled 2-arm parallel group study to compare efficacy, safety, and tolerability of CHF 5993 pMDI with CHF 1535 pMDI with respect to lung function, incidence of moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes.

After screening, eligible subjects will enter 2-week run-in period using their regular COPD maintenance therapies after which they will be randomized to one of 2 study treatment groups. Following randomization, subjects will be assessed after 4 weeks then at 6-week intervals thereafter for a period of 52 weeks. A follow-up safety phone call will be performed a week after the last clinic visit. A subset of subjects consenting to participate in the pharmacokinetic substudy will undergo additional assessments (totaling 3 visits) during the scheduled study visits.

During the study, daily symptoms, rescue medication use and compliance with the study drug will be recorded via a subject electronic diary. Subject concomitant medications, adverse events, and healthcare resource utilization will be assessed and recorded throughout the study. At intermittent study visits, subjects will undergo vital signs examinations including weight, spirometry measurements, and 12-lead ECG. Symptoms and COPD health status will be assessed through disease specific questionnaires. Routine hematology, blood chemistry, and serum pregnancy testing will be performed before enrollment and at end of study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • COPD
  • COPD Exacerbation
Intervention  ICMJE
  • Drug: Beclomethasone Dipropionate
    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
    Other Name: BDP
  • Drug: Glycopyrronium Bromide
    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
    Other Names:
    • glycopyrrolate
    • GB
  • Drug: Formoterol Fumarate
    Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
    Other Name: FF
Study Arms  ICMJE
  • Experimental: BDP/FF/GB - CHF 5993
    Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler
    Interventions:
    • Drug: Beclomethasone Dipropionate
    • Drug: Glycopyrronium Bromide
    • Drug: Formoterol Fumarate
  • Active Comparator: BDP/FF - CHF 1535
    Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
    Interventions:
    • Drug: Beclomethasone Dipropionate
    • Drug: Formoterol Fumarate
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 23, 2020)
2934
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2024
Estimated Primary Completion Date July 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed and dated written informed consent must be obtained prior to initiating any study-related procedures
  • Outpatient
  • Male or female subjects aged ≥40 years
  • A female is eligible to participate in the study if she is of non-childbearing potential defined as physiologically incapable of becoming pregnant OR childbearing potential with negative serum and urine pregnancy tests at screening, and is willing to use highly effective birth control methods for the full duration of the study
  • COPD diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report
  • Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]
  • COPD Assessment Test (CAT) score ≥10
  • A pre- and post-bronchodilator FEV1/FVC ratio <0.70 at screening
  • A post-bronchodilator FEV1 <50% predicted normal at screening and a documented history of ≥1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator FEV1 ≥50% and <80% of predicted normal at screening and a documented history of ≥2 moderate COPD exacerbations or ≥1 severe COPD exacerbation in the previous 12 months
  • Subjects receiving daily inhaled maintenance therapy for their COPD, at a stable dose for at least 3 months prior to the screening and randomization visits
  • Documentation (including imagery and report) of chest x-ray (CXR) or CT scan performed within 6 months prior to the screening visit, without evidence of significant abnormalities (other than those related to the presence of COPD).
  • A cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary.

Exclusion Criteria:

  • Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating
  • Subjects using the following medications prior to the screening visit and during the run-in period:

    1. Systemic/oral/parenteral corticosteroids in the prior 4 weeks
    2. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) or COPD exacerbation in the prior 4 weeks
    3. Any long-term chronic maintenance use of antibiotic treatment in the prior 4 weeks
    4. Oral xanthine derivatives (e.g. theophylline) in the prior 7 days
  • A moderate or severe COPD exacerbation or a respiratory tract infection (e.g., pneumonia) that has not resolved ≤14 days prior to the screening visit or during the run-in period
  • Current treatment with non-cardioselective β-blockers
  • Requirement of long term (> 15 hours daily) oxygen therapy
  • Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to investigator's judgement.
  • Lung transplant surgery or lung volume reduction surgery (subjects with lung volume reduction surgery are excluded if the procedure was performed within 1 year before the Screening visit)
  • Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator, would prevent use of anticholinergic agents
  • History of hypersensitivity to M3 receptor antagonists, β2 agonists, corticosteroids or any of the excipients contained in any of the study drugs used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement
  • Subject has severe, acute or uncontrolled cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class IV, left ventricular failure, acute myocardial infarction or unstable angina) in the last 6 months
  • An abnormal and clinically significant 12-lead ECG at either the screening or randomization visit. This is characterized as but not limited to any of the following findings:

    1. Atrial fibrillation (AF) with rapid ventricular response > 120 bpm
    2. Ventricular tachycardias (sustained, non-sustained [>3 up to 30 sec])
    3. Evidence of Mobitz Type II second degree or third-degree atrioventricular block
    4. Prolonged QTcF (>450ms for males, or >470ms for females). This criterion is not applicable for subjects with a pacemaker or permanent AF.
  • Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
  • Unstable or uncontrolled concurrent disease which may impact the efficacy or safety of the study drug or the subject's participation in the study according to investigator's judgment
  • Malignancy that has not been in complete remission for at least 1 year or any untreated localized carcinomas
  • History of alcohol abuse and/or substance/drug abuse (including marijuana inhaled and oral) within 12 months prior to the screening visit
  • Receipt of any other investigational drug within 1 month or 5 half-lives (whichever is greater) prior to the screening visit or have been previously randomized in this trial, or are currently participating in another clinical trial
  • Currently in the acute phase of a pulmonary rehabilitation program within 4 weeks before the screening visit or planning to enroll in the acute phase of such a program during the study. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
  • Mentally or legally incapacitated, or subjects incarcerated as a result of an official or judicial order
  • Major surgery in the 3 months prior to the screening visit or have a planned surgery during the trial
  • Non-satisfactory compliance with the eDiary (<65% or >135%) during the run-in period
  • Subjects requiring the use of spacer device or nebulizer for administration of maintenance COPD therapies.
  • Veins unsuitable for repeat venipuncture
  • Blood donation or blood loss (≥450mL) in the 4 weeks before randomization
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chiesi Clinical Trial Info +39 0521 2791 clinicaltrials_info@chiesi.com
Listed Location Countries  ICMJE Argentina,   Bulgaria,   Czechia,   Hungary,   Mexico,   Poland,   United States
Removed Location Countries Russian Federation,   Ukraine
 
Administrative Information
NCT Number  ICMJE NCT04320342
Other Study ID Numbers  ICMJE CLI-05993AA3-06
2020-002389-16 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Chiesi Farmaceutici S.p.A.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Chiesi Farmaceutici S.p.A.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Gregory M Feldman, MD Vitalink Research - Spartanburg
PRS Account Chiesi Farmaceutici S.p.A.
Verification Date February 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP